Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-MEDY: Dabigatran vs Warfarin for Extended VTE Treatment
NCT00329238Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2006
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of Recurrent VTE or VTE Death at 36 months. Started May 2006; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00329238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329238.